{"id":3933,"date":"2022-03-11T06:30:41","date_gmt":"2022-03-11T11:30:41","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/"},"modified":"2026-09-24T00:07:08","modified_gmt":"2026-09-24T04:07:08","slug":"gensight-biologics-annonce-son-calendrier-financier-pour-2022","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/","title":{"rendered":"GenSight Biologics annonce son  calendrier financier pour 2022"},"content":{"rendered":"\n<strong>\u00a0<\/strong>\n\n<strong>Paris, France, March 11, 2022, 7:30 am CET<\/strong> \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2022.\n\n&nbsp;\n<table>\n<tbody>\n<tr>\n<td width=\"323\"><strong>Information<\/strong><\/td>\n<td width=\"278\"><strong>Date* <\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"323\">2021 4Q Cash Position<\/td>\n<td width=\"278\">January 18, 2022<\/td>\n<\/tr>\n<tr>\n<td width=\"323\">2021 Full-Year Financial Update and Statements<\/td>\n<td width=\"278\">April 8, 2022 <sup>(1)<\/sup><\/td>\n<\/tr>\n<tr>\n<td width=\"323\">2022 1Q Cash Position<\/td>\n<td width=\"278\">April 21, 2022<\/td>\n<\/tr>\n<tr>\n<td width=\"323\">Annual General Meeting<\/td>\n<td width=\"278\">May 25, 2022<\/td>\n<\/tr>\n<tr>\n<td width=\"323\">2022 First-Half Financial Update and Statements<\/td>\n<td width=\"278\">July 28, 2022<\/td>\n<\/tr>\n<tr>\n<td width=\"323\">2022 3Q Cash Position<\/td>\n<td width=\"278\">October 27, 2022<\/td>\n<\/tr>\n<tr>\n<td width=\"323\">2022 4Q Cash Position<\/td>\n<td width=\"278\">January 26, 2023<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<em>(1) Initially planned on March 10, 2022<\/em>\n\n<em>* This financial calendar is provided for information only and may be subject to changes. The Company\u2019s updated financial calendar is available on its corporate website.<\/em>\n\n&nbsp;\n\n<span style=\"color: #33bdbc\"><strong>About GenSight Biologics <\/strong><\/span>\n\nGenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics\u2019 pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. Using its gene therapy-based approach, GenSight Biologics\u2019 product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics\u2019 lead product candidate, LUMEVOQ<sup>\u00ae<\/sup> (GS010; lenadogene nolparvovec), is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 Paris, France, March 11, 2022, 7:30 am CET \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2022. &nbsp; Information Date* 2021 4Q Cash Position January 18, 2022 [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[80],"post-year":[],"class_list":["post-3933","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-type-finance"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics annonce son calendrier financier pour 2022 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics annonce son calendrier financier pour 2022 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"\u00a0 Paris, France, March 11, 2022, 7:30 am CET \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2022. &nbsp; Information Date* 2021 4Q Cash Position January 18, 2022 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-11T11:30:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:07:08+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/03\\\/11\\\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/03\\\/11\\\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics annonce son calendrier financier pour 2022\",\"datePublished\":\"2022-03-11T11:30:41+00:00\",\"dateModified\":\"2026-09-24T04:07:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/03\\\/11\\\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\\\/\"},\"wordCount\":247,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/03\\\/11\\\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/03\\\/11\\\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\\\/\",\"name\":\"GenSight Biologics annonce son calendrier financier pour 2022 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-03-11T11:30:41+00:00\",\"dateModified\":\"2026-09-24T04:07:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/03\\\/11\\\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/03\\\/11\\\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/03\\\/11\\\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics annonce son calendrier financier pour 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics annonce son calendrier financier pour 2022 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics annonce son calendrier financier pour 2022 - GenSight Biologics","og_description":"\u00a0 Paris, France, March 11, 2022, 7:30 am CET \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2022. &nbsp; Information Date* 2021 4Q Cash Position January 18, 2022 [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/","og_site_name":"GenSight Biologics","article_published_time":"2022-03-11T11:30:41+00:00","article_modified_time":"2026-09-24T04:07:08+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics annonce son calendrier financier pour 2022","datePublished":"2022-03-11T11:30:41+00:00","dateModified":"2026-09-24T04:07:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/"},"wordCount":247,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/","name":"GenSight Biologics annonce son calendrier financier pour 2022 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2022-03-11T11:30:41+00:00","dateModified":"2026-09-24T04:07:08+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/03\/11\/gensight-biologics-annonce-son-calendrier-financier-pour-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics annonce son calendrier financier pour 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3933"}],"version-history":[{"count":3,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3933\/revisions"}],"predecessor-version":[{"id":7546,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3933\/revisions\/7546"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3933"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3933"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3933"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3933"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}